Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms

Area of Science:

• Oncology
• Translational Medicine
• Molecular Biology

Background:

• Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms.
• Advances in understanding NET biology, genetics, and immunology are driving therapeutic innovation.
• NETs are broadly classified into pancreatic (panNETs) and non-pancreatic (GI, thoracic) for treatment strategies.

Purpose of the Study:

• To review current and emerging targeted therapies for neuroendocrine tumors.
• To discuss treatment considerations for pancreatic versus non-pancreatic NETs.
• To highlight unmet needs in NET treatment sequencing, particularly regarding peptide receptor radionuclide therapy (PRRT).

Main Methods:

• Literature review of ongoing advances in NET biology and targeted therapies.
• Analysis of current treatment guidelines and emerging research for panNETs and non-pancreatic NETs.
• Discussion of the role of somatostatin analogs (SSAs), everolimus, PRRT, and VEGF TKIs.

Main Results:

• Treatment for panNETs prioritizes radiographic response, with targeted agents often used in later lines.
• For non-pancreatic NETs, SSAs are first-line, with everolimus and PRRT approved for subsequent lines.
• Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors (VEGF TKIs) show promise in research settings.

Conclusions:

• The expanding landscape of targeted therapies offers improved outcomes for NET patients.
• Optimal sequencing of therapies, including the timely integration of PRRT, represents a significant unmet need in NET management.
• Continued research into NET biology and treatment strategies is crucial for advancing patient care.